drugset
drugset / Trial / NCT02392377

Molecular Phenotyping in Predicting Response in Patients With Stage IB-III Esophageal Cancer Receiving Combination Chemotherapy

NCT02392377 ↗

Phase 2 Terminated 1 enrolled Case Comprehensive Cancer Center National Cancer Institute (NCI) · collab
RandomizedParallel-groupOpen-labelTreatment

Summary

This randomized pilot phase II trial studies how well molecular phenotyping works in predicting response in patients with stage IB-III esophageal cancer who are receiving carboplatin and paclitaxel or oxaliplatin, leucovorin calcium, and fluorouracil. Studying the genes in a patients tumor cells before and after chemotherapy may help in understanding if there are specific features of the tumor cells that make a person more or less likely to respond to treatment and how these features may be affected by treatment.

Timeline

Start
2015-02
Primary completion
2015-12
Completion
2015-12

Outcome

Outcome not reported

Stopped (Enrollment): “Slow accrual”

Drugs

EvaluationDrugModalityDoseRoute
Subject Carboplatin Small molecule — Intravenous
Subject Leucovorin Small molecule 400 mg/m2 Intravenous
Subject Oxaliplatin Small molecule 85 mg/m2 Intravenous
Subject Paclitaxel Small molecule 50 mg/m2 Intravenous
Subject Paclitaxel Small molecule 90 mg/m2 Intravenous
Subject fluorouracil Small molecule 300 mg/m2 Intravenous
Subject fluorouracil Small molecule 400 mg/m2 Intravenous
Subject fluorouracil Small molecule 2400 mg/m2 Intravenous

Indications

esophageal adenocarcinoma